Unknown

Dataset Information

0

Emerging role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.


ABSTRACT: Hepatocellular carcinoma is the most common primary liver cancer and the fourth leading cause of cancer death worldwide. A total of 70-80% of patients are diagnosed at an advanced stage with a dismal prognosis. Sorafenib had been the standardcare for almost a decade until 2018 when the Food and Drug Administration approved an alternative first-line agent namely lenvatinib. Cabozantinib, regorafenib, and ramucirumab also displayed promising results in second line settings. FOLFOX4, however, results inan alternative first-line treatment for the Chineseclinical oncology guidelines. Moreover,nivolumab and pembrolizumab,two therapeutics against the Programmed death (PD)-ligand 1 (PD-L1)/PD1 axis have been recently approvedfor subsequent-line therapy. However, similar to other solid tumors, the response rate of single agent targeting PD-L1/PD1 axis is low. Therefore, a lot of combinatory approaches are under investigation, including the combination of different immune checkpoint inhibitors (ICIs), the addition of ICIs after resection or during loco-regional therapy, ICIs in addition to kinase inhibitors, anti-angiogenic therapeutics, and others. This review focuses on the use of ICIs for the hepatocellular carcinoma with a careful assessmentof new ICIs-based combinatory approaches.

SUBMITTER: Longo V 

PROVIDER: S-EPMC6843273 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Emerging role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.

Longo Vito V   Brunetti Oronzo O   Gnoni Antonio A   Licchetta Antonella A   Delcuratolo Sabina S   Memeo Riccardo R   Solimando Antonio Giovanni AG   Argentiero Antonella A  

Medicina (Kaunas, Lithuania) 20191017 10


Hepatocellular carcinoma is the most common primary liver cancer and the fourth leading cause of cancer death worldwide. A total of 70-80% of patients are diagnosed at an advanced stage with a dismal prognosis. Sorafenib had been the standardcare for almost a decade until 2018 when the Food and Drug Administration approved an alternative first-line agent namely lenvatinib. Cabozantinib, regorafenib, and ramucirumab also displayed promising results in second line settings. FOLFOX4, however, resul  ...[more]

Similar Datasets

| S-EPMC6095178 | biostudies-literature
| S-EPMC7944520 | biostudies-literature
| S-EPMC8160723 | biostudies-literature
| S-EPMC7712941 | biostudies-literature
| S-EPMC10035682 | biostudies-literature
| S-EPMC7821931 | biostudies-literature
| S-EPMC6394775 | biostudies-literature
| S-EPMC8234948 | biostudies-literature
| S-EPMC7678689 | biostudies-literature
| S-EPMC9226303 | biostudies-literature